MedTrace Logo

MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction

NCT01319760 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-05-13

Study results available
· View outcomes & findings →

Summary

A prospective, randomized, controlled multi-site feasibility trial to assess the potential role of the IMPELLA® 2.5 System in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI)

Conditions

  • ST-elevation Myocardial Infarction

Interventions

DEVICE

Impella 2.5 support

Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5

OTHER

Standard of care (Control)

Standard care for STEMI patients post-PCI from ACC/AHA Guidelines

Sponsors & Collaborators

  • Abiomed Inc.

    lead INDUSTRY

Principal Investigators

  • Jeffrey Moses, MD · Columbia Presbyterian

  • Ajay Kirtane, MD · Columbia Presbyterian

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01319760 on ClinicalTrials.gov